Pivotal CIMZIA? Data In Crohn’s Disease Published In New England Journal Of Medicine
Two pivotal Phase III clinical trials demonstrating the safety and sustained efficacy of CIMZIA? (certolizumab pegol) in moderate-to-severe Crohn’s disease (CD) were published in two articles in the July 19 issue of the New England Journal of Medicine (NEJM).
